diaDexus to Present at the Oppenheimer Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D., president and chief executive officer, is scheduled to present at the Oppenheimer 24^th Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Ward will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.

Event:	Oppenheimer 24^thAnnual Healthcare Conference
Date:	Tuesday, December 10, 2013
Time:	3:55 p.m. Eastern Time

A live webcast of the presentation will be accessible on diaDexus' website at www.diaDexus.com. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation. A replay of the webcast will also be available after the conference concludes.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA₂ Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and manufactures the PLAC Test for Lp-PLA₂ Activity on-site. For more information, please visit the company's website at www.diaDexus.com.